CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
ResoTher Pharma is developing a novel peptide aimed at protecting heart tissue during reperfusion therapy for myocardial infarction. This innovative treatment seeks to reduce inflammation and cell death, potentially improving survival rates and outcomes for patients with ischemic heart disease.
Ischaemic heart disease (IHD) is the leading cause of mortality in Europe with about 1.8 million reported deaths per year inEurope alone. A serious consequence of IHD can be stopping blood flow to the heart causing a Myocardial Infarction (MI).
Inthe most severe cases this has a mortality rate between 6% and 14%.
Clinical guidelines recommend immediate restorationof the blood flow via reperfusion therapy.
However, this procedure results in high acute mortality (10%) and a significantincidence of…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
